Cerebrovascular disease and dementia

Drugs of Today

Volumn 41, Issue 12, 2005, Pages 815-825

  Srikanth, Velandai ^a   Saling, Michael M ^b   Thrift, Amanda G ^c   Donnan, Geoffrey A ^c  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CHOLINESTERASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGING; ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; ATHEROSCLEROSIS; BRAIN INFARCTION; BRAIN PERFUSION; CAUSAL ATTRIBUTION; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DEMENTIA; DIABETES MELLITUS; HUMAN; HYPOTENSION; META ANALYSIS; PATHOGENESIS; PHENOTYPE; PHYSICAL ACTIVITY; REVIEW; STROKE; SYSTEMATIC REVIEW; VASCULAR AMYLOIDOSIS; WHITE MATTER;

AGING; CEREBROVASCULAR DISORDERS; DEMENTIA; HUMANS;

EID: 33644672598     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.12.933473     Document Type: Review

References (81)

1. Knopman, D.S., DeKosky, S.T., Cummings, J.L. et al. Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56: 1143-53.
2. Hendrie, H.C. Epidemiology of dementia and Alzheimer's disease. Am J Geriatr Psychiatry 1998, 6(2 Suppl. 1): S3-18.
3. Anastas, J.W., Gibeau, J.L., Larson, P.J. Working families and eldercare: A national perspective in an aging America. Soc Work 1990, 35: 405-11.
4. World Health Organization special programme for research on aging: Description of program. World Health Organization (WHO), Geneva 1987.
5. Thrift, A.G., Dewey, H.M., Macdonell, R.A., McNeil, J.J., Donnan, G.A. Stroke incidence on the east coast of Australia: The North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2000, 31: 2087-92.
6. Sturm, J.W., Donnan, G.A., Dewey, H.M. et al. Quality of life after stroke: The North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2004, 35: 2340-5.
7. Dewey, H.M., Thrift, A.G., Mihalopoulos, C. et al. Cost of stroke in Australia from a societal perspective: Results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2001, 32: 2409-16.
8. Zhu, L., Fratiglioni, L., Guo, Z., Aguero-Torres, H., Winblad, B., Viitanen, M. Association of stroke with dementia, cognitive impairment, and functional disability in the very old: A population-based study. Stroke 1998, 29: 2094-9.
9. Roman, G.C. Facts, myths, and controversies in vascular dementia. J Neurol Sci 2004, 226: 49-52.
10. Caplan, L.R. Binswanger's disease - revisited. Neurology 1995, 45: 626-33.
11. Tomlinson, B.E., Blessed, G., Roth, M. Observations on the brains of demented old people. J Neurol Sci 1970, 11: 205-42.
12. Hachinski, V.C., Lassen, N.A., Marshall, J. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet 1994, 2: 207-10.
13. Tatemichi, T.K. How acute brain failure becomes chronic: A view of the mechanisms of dementia related to stroke. Neurology 1990, 40: 1652-9.
14. de la Torre, J.C. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma and dialectics. Lancet Neurol 2004, 3: 184-90.
15. Casserly, I., Topol, E. Convergence of atherosclerosis and Alzheimer's disease: Inflammation, cholesterol and misfolded proteins. Lancet 2004, 363: 1139-46.
16. Hatano, S. Experience from a multicentre stroke register: A preliminary report. Bull World Health Organ 1976, 54: 541-53.
17. Srikanth, V.K., Thrift, A.G., Saling, M.M. et al. Increased risk of cognitive impairment 3 months after mild to moderate first-ever stroke. A community-based prospective study of nonaphasic English-speaking survivors. Stroke 2003, 34: 1136-43.
18. Srikanth, V.K., Anderson, J.F., Donnan, G.A. et al. Progressive dementia after first-ever stroke: A community-based follow-up study. Neurology 2004, 63: 785-92.
19. Tournier-Lasserve, E., Joutel, A., Melki, J. et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nat Genet 1993, 3: 256-9.
20. O'Sullivan, M., Jarosz, J.M., Martin, R.J., Deasy, N., Powell, J.F., Markus, H.S. MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL. Neurology 2001, 56: 628-34.
21. Tatemichi, T.K., Desmond, D.W., Mayeux, R. et al. Dementia after stroke: Baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology 1992, 42: 1185-93.
22. Tatemichi, T.K., Paik, M., Bagiella, E. et al. Risk of dementia after stroke in a hospitalized cohort: Results of a longitudinal study. Neurology 1994, 44: 1885-91.
23. Desmond, D.W., Moroney, J.T., Sano, M., Stern, Y. Incidence of dementia after ischemic stroke: Results of a longitudinal study. Stroke 2002, 33: 2254-62.
24. Ivan, C.S., Seshadri, S., Beiser, A. et al. Dementia after stroke: The Framingham Study. Stroke 2004, 35: 1264-8.
25. Schneider, J.A., Wilson, R.S., Cochran, E.J. et al. Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology 2003, 60: 1082-8.
26. Tzourio, C., Anderson, C., Chapman, N. et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003, 163: 1069-75.
27. Henon, H., Durieu, I., Guerouaou, D., Lebert, F., Pasquier, F., Leys, D. Poststroke dementia: Incidence and relationship to prestroke cognitive decline. Neurology 2001, 57: 1216-22.
28. Snowdon, D.A., Greiner, L.H., Mortimer, J.A., Riley, K.P., Greiner, P.A., Markesbery, W.R. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997, 277: 813-7.
29. Vermeer, S.E., Den Heijer, T., Koudstaal, P.J., Oudkerk, M., Hofman, A., Breteler, M.M. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2003, 34: 392-6.
30. Vermeer, S.E., Prins, N.D., den Heijer, T., Hofman, A., Koudstaal, P.J., Breteler, M.M. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003, 348: 1215-22.
31. Breteler, M.M., van Swieten, J.C., Bots, M.L. et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: The Rotterdam Study. Neurology 1994, 44: 1246-52.
32. Prins, N.D., van Dijk, E.J., den Heijer, T. et al. Cerebral white matter lesions and the risk of dementia. Arch Neurol 2004, 61: 1531-4.
33. Falini, A., Barkovich, A.J., Calabrese, G., Origgi, D., Triulzi, F., Scotti, G. Progressive brain failure after diffuse hypoxic ischemic brain injury: A serial MR and proton MR spectroscopic study. AJNR Am J Neuroradiol 1998, 19: 648-52.
34. Hopkins, R.O., Tate, D.F., Bigler, E.D. Anoxic versus traumatic brain injury: Amount of tissue loss, not etiology, alters cognitive and emotional function. Neuropsychology 2005, 19: 233-42.
35. Royter, V., M. Bornstein, N., Russell, D. Coronary artery bypass grafting (CABG) and cognitive decline: A review. J Neurol Sci 2005, 229-230: 65-7.
36. Johnston, S.C., O'Meara, E.S., Manolio, T.A. et al. Cognitive impairment and decline are associated with carotid artery disease in patients without clinically evident cerebrovascular disease. Ann Intern Med 2004, 140: 237-47.
37. O'Connell, J.E., Gray, C.S., French, J.M., Robertson, I.H. Atrial fibrillation and cognitive function: Case-control study. J Neurol Neurosurg Psychiatry 1998, 65: 386-9.
38. Zuccala, G., Onder, G., Pedone, C. et al. Hypotension and cognitive impairment: Selective association in patients with heart failure. Neurology 2001, 57: 1986-92.
39. Kenny, R.A., Kalaria, R., Ballard, C. Neurocardiovascular instability in cognitive impairment and dementia. Ann NY Acad Sci 2002, 977: 183-95.
40. Roman, G.C. Brain hypoperfusion: A critical factor in vascular dementia. Neurol Res 2004, 26: 454-8.
41. Vinters, H.V., Gilbert, J.J. Cerebral amyloid angiopathy: Incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke 1983, 14: 924-8.
42. Revesz, T., Ghiso, J., Lashley, T. et al. Cerebral amyloid angiopathies: A pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 2003, 62: 885-98.
43. Haan, J., Algra, P.R., Roos, R.A. Hereditary cerebral hemorrhage with amyloidosis - Dutch type. Clinical and computed tomographic analysis of 24 cases. Arch Neurol 1990, 47: 649-53.
44. Greenberg, S.M., Gurol, M.E., Rosand, J., Smith, E.E. Amyloid angiopathy-related vascular cognitive impairment. Stroke 2004, 35(11 Suppl. 1): 2616-9.
45. Roob, G., Fazekas, F. Magnetic resonance imaging of cerebral microbleeds. Curr Opin Neurol 2000, 13: 69-73.
46. Kalaria, R.N. The blood-brain barrier and cerebral microcirculation in Alzheimer disease. Cerebrovasc Brain Metab Rev 1992, 4: 226-60.
47. Skoog, I., Lernfelt, B., Landahl, S. et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996, 347: 1141-5.
48. Qiu, C., von Strauss, E., Fastbom, J., Winblad, B., Fratiglioni, L. Low blood pressure and risk of dementia in the Kungsholmen project: A 6-year follow-up study. Arch Neurol 2003, 60: 223-8.
49. Guo, Z., Viitanen, M., Winblad, B., Fratiglioni, L. Low blood pressure and incidence of dementia in a very old sample: Dependent on initial cognition. J Am Geriatr Soc 1999, 47: 723-6.
50. Ruitenberg, A., Skoog, I., Ott, A. et al. Blood pressure and risk of dementia: Results from the Rotterdam Study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001, 12: 33-39.
51. Allen, K.V., Frier, B.M., Strachan, M.W. The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 2004, 490: 169-75.
52. Brands, A.M., Biessels, G.J., de Haan, E.H., Kappelle, L.J., Kessels, R.P. The effects of type 1 diabetes on cognitive performance: A metaanalysis. Diabetes Care 2005, 28: 726-35.
53. Strachan, M.W., Deary, I.J., Ewing, F.M., Frier, B.M. Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 1997, 20: 438-45.
54. Ott, A., Stolk, R.P., Hofman, A., van Harskamp, F., Grobbee, D.E., Breteler, M.M. Association of diabetes mellitus and dementia: The Rotterdam Study. Diabetologia 1996, 39: 1392-7.
55. Whitmer, R.A., Gunderson, E.P., Barrett-Connor, E., Quesenberry, C.P. Jr., Yaffe, K. Obesity in middle age and future risk of dementia: A 27 year longitudinal population based study. BMJ 2005, 330: 1360.
56. Rosengren, A., Skoog, I., Gustafson, D., Wilhelmsen, L. Body mass index, other cardiovascular risk factors, and hospitalization for dementia. Arch Intern Med 2005, 165: 321-6.
57. Podewils, L.J., Guallar, E., Kuller, L.H. et al. Physical activity, APOE genotype, and dementia risk: Findings from the Cardiovascular Health Cognition Study. Am J Epidemiol 2005, 161: 639-51.
58. Lindsay, J., Laurin, D., Verreault, R. et al. Risk factors for Alzheimer's disease: A prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002, 156: 445-53.
59. Seshadri, S., Beiser, A., Selhub, J. et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002, 346: 476-83.
60. Vermeer, S.E., van Dijk, E.J., Koudstaal, P.J. et al. Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study. Ann Neurol 2002, 51: 285-9.
61. den Heijer, T., Vermeer, S.E., van Dijk, E.J. et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003, 46: 1604-10.
62. Flicker, L., Martins, R.N., Thomas, J. et al. Homocysteine, Alzheimer genes and proteins, and measures of cognition and depression in older men. J Alzheimers Dis 2004, 6: 329-36.
63. Hasegawa, T., Ukai, W., Jo, D.G. et al. Homocysteic acid induces intraneuronal accumulation of neurotoxic Abeta42: Implications for the pathogenesis of Alzheimer's disease. J Neurosci Res 2005, 80: 869-76.
64. Letenneur, L. Risk of dementia and alcohol and wine consumption: A review of recent results. Biol Res 2004, 37: 189-93.
65. Dufouil, C., Richard, F., Fievet, N. et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: The Three-City Study. Neurology 2005, 64: 1531-8.
66. Kivipelto, M., Helkala, E.L., Laakso, M.P. et al. Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. BMJ 2001, 322: 1447-51.
67. Tan, Z.S., Seshadri, S., Beiser, A. et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: The Framingham Study. Arch Intern Med 2003, 163: 1053-7.
68. Lahiri, D.K., Sambamurti, K., Bennett, D.A. Apolipoprotein gene and its interaction with the environmentally driven risk factors: Molecular, genetic and epidemiological studies of Alzheimer's disease. Neurobiol Aging 2004, 25: 651-60.
69. Farkas, E., Donka, G., de Vos, R.A., Mihaly, A., Bari, F., Luiten, P.G. Experimental cerebral hypoperfusion induces white matter injury and microglial activation in the rat brain. Acta Neuropathol (Berl) 2004, 108: 57-64.
70. Frackowiak, J., Miller, D.L., Potempska, A., Sukontasup, T., Mazur-Kolecka, B. Secretion and accumulation of Abeta by brain vascular smooth muscle cells from A-beta-PP-Swedish transgenic mice. J Neuropathol Exp Neurol 2003, 62: 685-96.
71. de la Torre, J.C., Pappas, B.A., Prevot, V. et al. Hippocampal nitric oxide upregulation precedes memory loss and A beta 1-40 accumulation after chronic brain hypoperfusion in rats. Neurol Res 2003, 25: 635-41.
72. Aliev, G., Smith, M.A., Obrenovich, M.E., de la Torre, J.C., Perry, G. Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease. Neurotox Res 2003, 5: 491-504.
73. Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., Damaraju, C.V. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet 2002, 359: 1283-90.
74. Goldsmith, D.R., Scott, L.J. Donepezil: In vascular dementia. Drugs Aging 2003, 20: 1127-36.
75. Feigin, V., Ratnasabapathy, Y., Anderson, C. Does blood pressure lowering treatment prevent dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J Neurol Sci 2005, 229-230: 151-5.
76. Rationale and design of the ADVANCE study. A randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation. J Hypertens Suppl 2001, 19: S21-8.
77. Jick, H., Zornberg, G.L., Jick, S.S., Seshadri, S., Drachman, D.A. Statins and the risk of dementia. Lancet 2000, 356: 1627-31.
78. Blauw, G.J., Shepherd, J., Murphy, M.B. Dementia and statins. PROSPER study group. Lancet 2001, 357: 881.
79. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002, 360: 7-22.
80. Schwammenthal, Y., Tanne, D. Homocysteine, B-vitamin supplementation, and stroke prevention: From observational to interventional trials. Lancet Neurol 2004, 3: 493-5.
81. Malouf, M., Grimley, E.J., Areosa, S.A. Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst Rev 2003, CD004514.